EPI-331

Asset

CRISPR-based epigenome editing provides a mutation-agnostic approach to treating Duchenne muscular dystrophy.

Stage
Stage not known
Modality
Not known
Target
Not known
0
Indications
0
Trials
1
Developer

Indications

0

    In the full profile

    • Owner and partners1

    Every asset’s record: target, stage, trials and the evidence behind it.

    See Pro

    Assets